Abstract
Radiolabelled somatostatin analogues are of potential value in the imaging of somatostatin receptor-positive tumours. Recently, somatostatin receptors have been demonstrated in the osteoblast precursor cells. In this preliminary study, we evaluated the uptake characteristics of indium-111 octreotide in two benign and two malignant bone tumours. Tracer accumulation was observed in all four cases, and overall lesion to background ratio (mean±SD) was 2.74±0.84 and 2.98±1.49 at 4 h and 24 h, respectively. There was no clear relationship between I111In-octreotide accumulation and the benign or malignant nature of the tumour. In one patient, tracer uptake was inhibited by unlabelled octreotide administration. These results suggest that111In-octreotide can be taken up by benign and malignant bone tumours. The inhibition of tumour uptake by treatment with cold octreotide supports the concept that specific uptake mechanisms are responsible for111In-octreotide deposition by bone tumours.
This is a preview of subscription content, log in via an institution to check access.
References
Reihlin S. Somatostatin.N Engl J Med 1983; 309: 1495–1563.
Brazeau P, Vale W, Burgus R, etal. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.Science 1973; 179: 77–79.
Silve C, Lieberherr M, Garabedian M, et al. Somatostatin and vitamin D3 metabolites in rat calvarium: in vitro evidence for physiological interaction.Endocrinology 1981; 109: 1454–1462.
Mackie EJ, Trechsel U, Burns C. Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during enchondral bone formation.Development 1990; 110: 1233–1239.
Bakker, WH, Krenning EP, Reubi JC, et al. In vivo application of ln-111-DTPA-D-Phe-octreotide for detection of somatostatin receptor-positive tumours in rats.Life Sci 1991; 49: 1593–1601.
Hiruma K, Koike T, Nakamura H, et al. Somatostatin receptors on human lymphocytes and leukemia cells.Immunology 1990; 71: 480–485.
Krenning EP, Kwekkkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with In-111-DTPA-d-Phe-octreo-tide and I-123-Tyr-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716–731.
Öztürk E, Günalp B, Özgüven M, et al. The visualization of granulomatous disease with somatostatin receptor scintigraphy.Clin Nucl Med 1994; 19: 129–132.
Anderson JV, Bloom SR. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.Scand J Gastroenterol 1986; 21: 115–128.
Lamberts SWJ, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Eng J Med 1985; 313: 1576–1580.
Shally AV. Oncological applications of somatostatin analogues.Cancer-Res 1988; 48: 6977–6985.
Redding TW, Schally AV. Inhibition of growth of the transplantable rat chondrosarcoma by analogues of hypothalamic hormones.Proc Natl Acad Sci USA 1983; 80: 1078–1082.
Ghanta VK, Hiromato RN, Weiss AB, Caudill LJ. Monitoring of murine osteosarcoma by serial alkaline phosphatase determinations.J Natl Cancer Inst 1976; 57: 837–839.
Penn RD, Paice JA, Kroin JS. Intrathecal octreotide for cancer pain.Lancet 1990; 24: 238.
Campanacci M. Chondroblastoma. In: Campanacci M, Enneking FW, eds.Bone and soft tissue tumours. Vienna New York: Springer; 1990: 241–252.
Oyen WIG, Boerman OC, Claessens RAMJ, Van Der Meer JWM, Corstens FHM. Is somatostatin receptor scintigraphy suited to detection of acute infectious disease?Nucl Med Commun 1994; 15: 289–293.
Pagliacci MC, Tognellini R, Grignani F, Nicoletti I. Inhibition of human breast cancer cell (MCF-7) growth in vitro by somatostatin analogue SMS 201-995: effects on cell cycle parameters and apoptotic cell death.Endocrinology 1991; 129: 2555–2562.
Silve C, Lieberherr M, Garabedian M, et al. Somatostatin and vitamin D3 metabolites in rat calvarium: in vitro evidence for physiological interaction.Endocrinology 1981; 109: 1454–1462.
Krenning EP, Kooji PPM, Bakker WH. Radiotherapy with a radiolabelled somatostatin analogue.Ann NY Acad Sci 1994; 773: 496–506.
Wiseman GA, Kvols LK. Therapy of neuroendocrine tumours with radiolabelled MIBG and somatostatin analogues.Semin Nucl Med 1995; 25: 272–278.
Adamo V, Altavilla G, Caristi N, et al. Somatostatin analogue octreotide in metastatic breast cancer (BC) and prostate cancer (PC).Eur J Cancer 1991; 27: S312.
Libroia A, Verga U, Sacco G, Piolini M, Muratori F. Use of somatostatin analogue SMS 201–995 in medullary thyroid carcinoma.Henry Ford Hosp Med J 1989; 37: 151–153.
Macaulay VM, Smith IE, Everard MJ, et al. Experimental and clinical studies with somatostatin analogue otreotide in small cell lung cancer.Br J Cancer 1991; 64: 451–456.
Iftikhar SY, Watson S, Morris DL. Effect of SMS 201–995 on serum tumour marker, mitotic index and gastrin immunoreactivity in colorectal cancer.Br J Cancer 1990; 17: 1416.
Flamen PF, Bossuyt A, Greve JD, et al. Imaging of renal call carcinoma with radiolabelled octreotide.Nucl Med Commun 1993; 14: 873–877.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inanir, S., Ünlü, M., Okudan, B. et al. Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities. Eur J Nucl Med 23, 987–990 (1996). https://doi.org/10.1007/BF01084376
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01084376